Read the July/August edition of Pharmafocus online now!
pharmafile | June 28, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | NHS, Orkambi, Trump, UK, brexit, generics, manufacturing compliance, pharma
The latest monthly edition of Pharmafocus, the July/August issue, is available to read for free online now!
The UK remains split right down the middle as the Brexit crisis rolls on and on, and while we have been side-tracked from one political wedge to focus on another – the race to become the new leader of the Conservative Party, and, ultimately, the next Prime Minister – there is still one issue that never fails to heal the divide: the defence of the NHS.
This was proven once again earlier in June, when American Ambassador to the UK and Johnson & Johnson heir Woody Johnson’s suggestion that the health service could be “on the table” in post-Brexit trade negotiations was met with scorn on both sides of the aisle. You can read the full story on our front page this month.
Elsewhere in the UK, the Orkambi access dispute continues as Vertex and NHS England squabble over the availability of the cystic fibrosis drug. Patients are now taking the matter into their own hands with the establishment of a ‘Buyers’ club’, hoping to import generic versions of the medicine from Argentina. You can read the full details on page 5, with exclusive comment from Nick Medhurst, Head of Policy and Public Affairs at the Cystic Fibrosis Trust.
On a global scale, news has broken that 2018 was a record-breaking year for cancer drug launces, with more successfully hitting markets than any previous year. However, reports indicate, as if it wasn’t threatening enough, that climate change could fuel the spread of dengue fever into previously safe regions of the world. You can check out more on pages 7 and 8.
We also have full length features on manufacturing compliance – where Louis Goss quizzes investigative journalist Katherine Eban on her book Bottle of Lies, and its shocking findings on the generic drug industry – and patient-reported outcomes measures, where Matt Fellows examines how effective the use of such measures is in meeting the needs of today’s patients.
Related Content
NICE recommends migraine treatment for NHS use
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …
Novo Nordisk launches Wegovy in the UK
Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
